IL17A and skin infection: It was therefore investigated if the use of a novel adjuvant, LP1569 + cyclic-di-GMP (cGMP), which has previously been shown to be a potent IL-17–inducing adjuvant (44, 45), could similarly protect against S. aureus skin infection through induction of protective IL-17 responses (46).